Century Ply Reports 49% Surge in Q4 Profit as Revenue Reaches All-Time High Driven by Strong Demand for Plywood and Laminates

Century Ply Reports 49% Surge in Q4 Profit as Revenue Reaches All-Time High Driven by Strong Demand for Plywood and Laminates
Century Plyboards (India) Ltd delivered impressive results for the March quarter, with consolidated net profit soaring 48.8% year-on-year, fueled by strong growth in its plywood and laminates sectors.

The company reported a consolidated net profit of ₹78.1 crore for FY26’s fourth quarter, up from ₹52.5 crore in the same period last year.

Revenue from operations grew 24.5% year-on-year to ₹1,492.2 crore, compared to ₹1,198.3 crore a year prior, achieving the company’s highest quarterly revenue to date.
EBITDA saw a 31.8% increase to ₹177.4 crore in the quarter, versus ₹134.6 crore in the previous year’s corresponding period. The EBITDA margin rose to 12% from 11%.
The company noted that its plywood business persisted in generating sustainable growth both sequentially and annually, aided by enhanced profitability.

Century Plyboards also emphasized a robust recovery in its laminates division, which had been relatively stagnant over the past two years. This segment experienced significant revenue growth and margin improvement during FY26, indicating a rebound in demand and operational efficiency.

The board of directors suggested a dividend of ₹1 per equity share of face value ₹1 each for the financial year ending March 31, 2026, pending approval from shareholders at the upcoming annual general meeting.

The company revealed changes at the board level, with Nikita Bansal reappointed as Executive Director for another five-year term starting February 1, 2027. Additionally, Rakesh Kumar Jain was named an Additional Director in the Independent category for a five-year term effective May 22, 2026.

Shares of Century Plyboards India closed 0.45% higher at ₹769.95 each on the NSE before the earnings announcement.

Also Read: Gujarat Themis Biosyn to acquire Japan’s MicroBiopharm for ₹1,300 crore

Previous Article

India's economy has faced numerous challenges. What keeps it resilient?

Next Article

Unichem Laboratories Reports 79% Decline in Q4 Net Profit Due to Extraordinary Items